Casa Santa Isabel · independent assessment framework

Clinical Standards

A careful way to assess what an ibogaine treatment program should be able to document: governance, patient selection, treatment safety, continuity of care, and evidence.

These are benchmarks for evaluating claims about Casa Santa Isabel, not findings that the clinic meets them.

Quiet clinical interior illustrating the need for structured safety standards in ibogaine care

A standard is useful when it can be checked with specific documentation.

The purpose of a benchmark

Ask for records, not reassurance.

Ibogaine treatment can involve serious medical risk, including cardiac risk. For people assessing Casa Santa Isabel, the central question is not whether safety language appears in promotional material; it is whether the program can explain and document the safeguards behind that language. The broader ibogaine safety framework on Rosarithm is designed around that distinction.

Ibogaine is a psychoactive alkaloid associated with documented cardiac safety concerns, and regulators have not established it as an approved treatment in the United States. The U.S. Food and Drug Administration’s drug-safety information is a useful reminder that treatment decisions should not rest on marketing claims alone.

Verifiable standards do not promise a safe outcome. They make it possible to examine whether meaningful risk controls are present, current, and specific.

This page does not provide medical advice or certify any program. It sets out practical benchmarks and the kinds of objective material a prospective patient or family member could reasonably request before treating a clinical claim as established.

Domains one and two

Governance and patient selection

These two domains determine who is accountable for care and how a program decides whether treatment should proceed at all.

Governance has named accountability.

A credible program should be able to identify the legal entity operating the setting, the applicable license or authorization where relevant, and the clinician with responsibility for medical decisions. A title alone is not enough; ask what role the person holds, where their professional standing can be checked, and who has authority to stop or escalate treatment.

Operating license or applicable authorization
Medical director’s role and credentials
Written escalation and incident procedures
Clear responsibility for clinical decisions

Screening is more than a questionnaire.

Patient selection should involve a defined clinical review of medical history, current medicines, substance use, and contraindications—not a broad assurance that someone is “a candidate.” The screening and contraindications overview helps frame questions about whether exclusions, medication changes, and referral decisions are documented and reviewed by an appropriately qualified clinician.

Written intake and exclusion criteria
Medication reconciliation process
Documented clinical review before treatment
Plan for people who should not proceed

Decisions should be explainable after the fact.

A program should be able to describe when it pauses, postpones, or declines treatment, and what documentation supports that decision. This matters particularly when people are navigating complex opioid histories; questions raised by methadone and ibogaine are not resolved by a generic claim that a protocol is individualized.

Decision criteria for delay or refusal
Record of relevant clinical findings
Written explanation of referral pathways
Process for informed consent and questions

Clinical setting emphasizing careful monitoring and emergency readiness during ibogaine treatment

Domain three

Treatment safety must address cardiac risk.

Cardiac assessment and monitoring are central questions for any ibogaine program. Ibogaine has been associated with QT interval prolongation and potentially dangerous rhythm disturbances; the published clinical literature on ibogaine-related cardiotoxicity describes why a program’s cardiac safeguards need to be concrete rather than implied.

Ask whether pre-treatment ECG assessment is part of a written protocol, how medication and electrolyte risks are evaluated, who interprets findings, and what level of ECG or other monitoring is used during and after administration. It is also reasonable to ask for the program’s policy on electrolyte assessment and correction, including how it considers questions sometimes raised around magnesium in ibogaine protocols.

Emergency planning should include more than an emergency kit. A meaningful answer identifies the trained personnel available, the equipment and monitoring capability in use, thresholds for escalation, and a current agreement or documented pathway for hospital transfer. A location that cannot explain its emergency transfer process leaves an important safety claim untested.

Domains four and five

Continuity of care and evidence require a paper trail.

Discharge is not the end of a clinical responsibility. A credible continuity plan describes what support follows treatment, how new or worsening symptoms are handled, what information is given to the patient, and how ongoing care is coordinated where appropriate. This is especially important when the stated goal concerns dependency or withdrawal; discussions of ibogaine withdrawal should not stand in for a documented follow-up pathway.

Evidence and transparency are related but distinct. A program can state that it follows best practices, but a prospective patient should still ask which protocol, guideline, or internal policy supports that statement, when it was last reviewed, and what outcome or adverse-event records are kept. The practical transparency checklist can help separate specific answers from broad assurances.

Public discussion of ibogaine often uses language about recovery, transformation, or identity. Those themes, including claims about ibogaine and ego, should remain separate from clinical safety evidence. A clinical standard concerns the process a program can document—not the intensity of an individual narrative.

Because treatment access and oversight can differ substantially across jurisdictions, comparisons with ibogaine options beyond Mexico should focus on what can be verified in each setting: credential checks, written protocols, monitoring arrangements, and continuity planning. The same approach applies when reviewing broader directories such as ibogaine treatment centers in the United States.

Questions for evaluation

A clear answer is usually a specific one.

Does this page say Casa Santa Isabel meets these standards?

No. These are benchmarks and documentation types to request when assessing claims. Rosarithm does not verify or certify a clinic’s compliance through this page.

What should documented follow-up show?

It should describe who follows the patient after discharge, what escalation route exists for concerning symptoms, and how the plan is shared with appropriate ongoing care providers. This is part of evaluating continuity—not a substitute for medical advice.

Why is transparency part of a clinical standard?

Because written, specific answers allow a person to distinguish a stated safeguard from a verifiable process. Clear documentation does not eliminate risk, but it makes safety claims easier to evaluate. For the broader purpose and limits of this work, see Rosarithm’s independent-resource approach.

Keep the questions specific

A checklist is not a verdict.

Use these standards to identify what a program can document, where its answers remain unclear, and which questions require independent professional guidance before any treatment decision.

Use the transparency checklist